Critical review of lipid amphotericin B formulations as treatment of invasive aspergillosis in patients with hematological disorders or bone marrow transplantation (BMT)

Journal de Mycologie Medicale

Volumn 6, Issue SUPPL. 1, 1996, Pages 17-20

  Ribaud, P ^a   Gluckman, E ^a  

^a SAINT LOUIS HOSPITAL   (France)

Author keywords

aspergillosis; bone marrow transplantation; lipid amphotericin B

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B LIPID COMPLEX;

ASPERGILLOSIS; BONE MARROW TRANSPLANTATION; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; HUMAN;

EID: 0029817128     PISSN: 11565233     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (12)

1. Bowden RA, Cays M. Phase I safety study of Amphotericin B colloidal dispersion (ABCD: Amphocil) for the treatment of invasive fungal infection after marrow transplant. The Annual Meeting of the American Society of Hematology, St Louis, MO, December 1993, abstract 1685.
2. Chopra R, Blair S, Strang J, Cervi P, Patterson G, Goldstone AH. Liposomal amphotericin B (AmBisome) in the treatment of fungal infections in neutropenic patients. J Antimicrob Chemother 1991;28(suppl. B):93-104.
3. de Marie S, Janknegt R, Bakker-Woudenberg AJM. Clinical use of liposomal and lipid-complexed amphotericin B. J Antimicrob Chemother 1994;33:907-16.
4. Drakos PE, Nagler A, Or R, Naparstek E, Kapelushnik J, Engelhard D, Rahav G, Ne'emean D, Slavin S. Invasive fungal sinusitis in patients undergoing bone marrow transplantation. Bone Marrow Transplant 1993;12:203-8.
5. Hiemenz JW, Anaissie FJ, Walsh TJ. Amphotericin B lipid complex for the treatment of severe systemic mycosis in patients with hematologic malignancies. The Annual Meeting of the American Society of Hematology, Nashville, Tennessee, December 1994, abstract 1207.
6. Medoff G, Dismukes WE, Pappagianis D, Diamond R, Gallis HA, Drutz D. General guidelines for the evaluation of new antifungal drugs for the treatment of systemic fungal infection. Clin Infect Dis 1992;15(Suppl. 1):274-81.
7. Mills W, Chopra R, Linch DC, Goldstone AH. Liposomal amphotericin B in the treatment of fungal infections in neutropenic patients: a single-center experience of 133 episodes in 116 patients. Br J Haematol 1994;86:754-60.
8. Oppenheim BA, Herbrecht R, Kusne S. The satefy and efficacy of Amphotericin B Colloidal Dispersion in the treatment of invasive mycoses. Clin Infect Dis 1995;21:1145-53.
9. Pagliuca A, Mufti GJ. Successful outcome in invasive pulmonary aspergillosis using liposomal amphotericin. 20th Annual Meeting of the European Group for Bone Marrow Transplantation, Harrogate, UK, April 1994, abstract 282.
10. Ringden O, Meunier F, Tollemar J, Ricci P, Tura S, Kuse E, Viviani MA, Gorin NC, Klastersky J, Frenaux P, Prentice HG, Ksionki G. Efficacy of amphotericin B encapsulated in liposomes (AmBisome) in the treatment of invasive fungal infections in immunocompromised patients. J Antimicrob Chemother 1991;28(suppl. B):73-82.
11. Walsh TJ, Hiemenz JW, Scibel N, Anaissie EJ. Amphotericin B Lipid Complex in the treatment of 228 cases of invasive mycosis. 34th Interscience Conference on Antimicrobial Agents and Chemotherapy, Orlando, Floride, October 1994, 247, abstract M69.
12. Wingard J, Walker RC. Efficacy of Amphotericin B Lipid Complex in the treatment of bone marrow transplant recipients with life-threatening systemic mycoses. The Annual Meeting of the American Society of Hematology, Nashville, Tennessee, December 1994, abstract 1928.